Does State Medicaid Cover Zepbound?

Why Medicaid Coverage for Zepbound Is So Inconsistent

State Medicaid programs operate under federal guidelines but retain broad discretion over their preferred drug lists (PDLs). Each state negotiates its own supplemental rebates with manufacturers, sets its own formulary tiers, and determines which indications qualify for reimbursement. The result is a patchwork where a patient in one state may receive Zepbound at no out-of-pocket cost while a patient 20 miles across the border faces a flat denial.

The Centers for Medicare & Medicaid Services (CMS) has historically excluded weight-loss drugs from the mandatory Medicaid drug rebate program under the Social Security Act §1927(d)(2). This optional exclusion means states are not required to cover anti-obesity medications (AOMs) at all. Some states, including New York and a handful of others, have voluntarily added select AOMs to their PDLs. Many have not.

Tirzepatide (brand name Zepbound for obesity, Mounjaro for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist. The FDA approved Zepbound in November 2023 specifically for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. In the SURMOUNT-1 trial (N=2,539), participants receiving tirzepatide 15 mg lost a mean of 22.5% of body weight at 72 weeks compared with 2.4% for placebo. That level of efficacy is difficult for payers to ignore.

Yet budget impact is the countervailing force. At $1,059 per month, covering Zepbound for the estimated 42% of Medicaid enrollees who meet BMI criteria would cost states billions annually, according to a KFF analysis of Medicaid AOM spending.

The Federal Policy Shift That Could Change Everything

Federal law has long permitted states to exclude AOMs from Medicaid. That may change. The Treat and Reduce Obesity Act, reintroduced in Congress in 2024, would require Medicaid coverage of FDA-approved AOMs. As of May 2026, the bill has not passed. But CMS issued guidance in late 2024 encouraging states to consider covering AOMs for enrollees with obesity-related comorbidities, citing long-term cost offsets from reduced cardiovascular events, fewer joint replacements, and lower rates of type 2 diabetes progression.

A 2023 study in JAMA Network Open modeled the budget impact of Medicaid AOM coverage across 10 states and found that net costs depended heavily on supplemental rebate negotiations. States that secured rebates of 50% or more projected near-neutral 5-year budget impact when accounting for avoided downstream medical costs.

The practical effect for patients right now: if your state Medicaid plan does not list Zepbound on its PDL for obesity, no amount of prior authorization paperwork will override that exclusion. The drug simply is not a covered benefit. Step one is always confirming whether your state covers AOMs at all.

Which States Currently Cover GLP-1s for Obesity Under Medicaid?

No centralized, real-time database tracks every state's Medicaid PDL for AOMs. Coverage changes quarterly as states renegotiate rebates and update formularies. The following reflects the best available data as of early 2026.

States that have added at least one GLP-1 receptor agonist for weight management to their Medicaid PDL include New York, California, Massachusetts, Minnesota, Connecticut, Oregon, and several others. Not all of these states specifically list Zepbound; some cover only semaglutide (Wegovy) or liraglutide (Saxenda) and require prior authorization denials before considering tirzepatide as a non-preferred alternative.

States that explicitly exclude all AOMs from Medicaid coverage as of early 2026 include Texas, Florida, Georgia, Tennessee, and others. In these states, the only pathway to tirzepatide coverage under Medicaid is through a type 2 diabetes diagnosis using the Mounjaro brand, not Zepbound.

To check your state's current formulary, search "[your state] Medicaid preferred drug list" or contact your managed care organization (MCO) directly. Many states contract with MCOs that maintain their own sub-formularies, adding another layer of variation. A drug excluded from the state's fee-for-service PDL may occasionally appear on an MCO's formulary, and vice versa.

Prior Authorization Criteria for Zepbound on Medicaid

In states where Zepbound is a covered benefit for chronic weight management, prior authorization (PA) is required in virtually every case. The specific criteria vary, but common requirements include the following.

BMI documentation. The prescriber must document a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity. Some states require the BMI to be confirmed by a measurement taken within 90 days of the PA request. Others accept the most recent documented BMI in the medical record.

Lifestyle modification history. Most states require evidence that the patient has participated in a structured diet and exercise program for a minimum of 3 to 6 months before the PA request. Documentation typically includes dietitian referrals, behavioral counseling records, or enrollment in a recognized weight management program.

Step therapy failures. The majority of covering states mandate failure of, intolerance to, or contraindication with at least one first-line AOM before approving Zepbound. Common required step-therapy agents include phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and in some states, orlistat. A few states also require documented failure of semaglutide 2.4 mg (Wegovy) before approving tirzepatide.

Specialist involvement. Certain states require the prescription to originate from or be co-signed by an endocrinologist, obesity medicine specialist, or bariatric surgeon. Primary care prescriptions may be rejected on this basis alone.

Renewal criteria. Initial PA approvals typically last 6 to 12 months. Renewal requires documentation that the patient has achieved a minimum of 5% total body weight loss from baseline. Failure to meet this threshold results in discontinuation of coverage.

According to the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity, tirzepatide is recommended as a first-line pharmacotherapy option for adults with obesity, with the Society explicitly noting that step therapy requirements "may delay access to the most effective available agents." This guideline gives prescribers evidence-based ammunition when challenging step therapy mandates.

Step Therapy: What You Need to Fail First

Step therapy is the single most common barrier to Zepbound coverage under Medicaid. The rationale is cost containment: states want patients to try less expensive medications first. Here is what that looks like in practice.

Step 1 (most states): Generic phentermine (approximately $30 to $60 per month) for 3 months. Phentermine is FDA-approved only for short-term use (up to 12 weeks), which creates an inherent contradiction in step therapy protocols that require a 3-month trial.

Step 2 (some states): Naltrexone-bupropion (Contrave) or phentermine-topiramate (Qsymia) for 3 to 6 months. These medications produce mean weight loss of 5% to 9% in clinical trials, significantly less than tirzepatide's 22.5% in SURMOUNT-1.

Step 3 (select states): Semaglutide 2.4 mg (Wegovy) for 3 to 6 months. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo. States that require Wegovy failure before approving Zepbound are essentially requiring failure of the second most effective AOM on the market.

The total time from initial prescription to Zepbound approval under a 3-step protocol can exceed 12 months. During that time, patients with obesity continue to face elevated risks of cardiovascular disease, type 2 diabetes, and other complications. Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has described mandatory step therapy for AOMs as "a system designed to delay the most effective treatments for the patients who need them most."

Prescribers can sometimes bypass step therapy by documenting clinical contraindications to the required first-step agents. Phentermine is contraindicated in patients with uncontrolled hypertension, hyperthyroidism, or a history of cardiovascular disease. Topiramate is contraindicated in pregnancy and carries teratogenic risk. Documenting these contraindications can shorten the step therapy pathway.

How to Appeal a Medicaid Denial of Zepbound

When Medicaid denies a PA request for Zepbound, the denial letter must include the specific reason for denial and instructions for filing an appeal. The process follows a defined pathway in every state.

Step 1: Internal appeal. File a written appeal with the MCO or state Medicaid agency within the timeframe specified in the denial letter (typically 30 to 60 days). Include a letter of medical necessity from the prescribing physician, relevant clinical documentation (BMI history, comorbidity records, prior medication trials and outcomes), and supporting clinical evidence such as the SURMOUNT trial data and the Endocrine Society guideline.

Step 2: External review or fair hearing. If the internal appeal is denied, every state Medicaid program provides a fair-hearing process. This is an administrative hearing before an independent reviewer. Patients can represent themselves or bring an advocate. The hearing examiner reviews whether the denial was consistent with the state's published coverage criteria and federal Medicaid regulations.

Step 3: Expedited review. If the prescribing physician certifies that delay would seriously jeopardize the patient's health, an expedited review can be requested. Under federal rules, expedited decisions must be rendered within 72 hours. Standard timelines for fair hearings vary by state but typically range from 30 to 90 days.

Key documentation to include in any appeal:

• Complete medication history showing prior AOM trials and failures
• Longitudinal BMI records demonstrating the chronic nature of the condition
• Records of obesity-related comorbidities (sleep studies, hemoglobin A1c trends, blood pressure logs, lipid panels)
• A letter from the prescriber citing the SURMOUNT-1 efficacy data and explaining why tirzepatide is the appropriate next step
• The FDA-approved prescribing information for Zepbound to confirm the indication matches the patient's clinical profile

A 2024 analysis published in Obesity found that PA denials for GLP-1 receptor agonists were overturned on appeal in approximately 40% of cases when the appeal included a detailed letter of medical necessity with clinical trial citations.

The Manufacturer Savings Card and Medicaid

Eli Lilly offers a savings card program for Zepbound that can reduce out-of-pocket costs for commercially insured patients. Medicaid beneficiaries are not eligible. This is not an Eli Lilly policy; it is a federal restriction.

The Anti-Kickback Statute and the Medicaid Best Price rule prohibit manufacturers from offering copay assistance to patients covered by federal healthcare programs, including Medicaid, Medicare, and TRICARE. If a manufacturer offers a lower effective price to Medicaid patients through a savings card, that price could reset the "best price" used to calculate mandatory Medicaid rebates across all states, significantly increasing the manufacturer's rebate obligations.

For Medicaid patients who cannot obtain coverage for Zepbound, alternative pathways include:

• Patient assistance programs. Eli Lilly's Lilly Cares Foundation provides free medications to qualifying uninsured and underinsured patients. Medicaid patients who have been denied coverage may qualify.
• 340B pricing. Patients receiving care at 340B-covered entities (federally qualified health centers, disproportionate share hospitals) may access Zepbound at significantly reduced cost.
• State pharmaceutical assistance programs (SPAPs). A small number of states operate SPAPs that supplement Medicaid coverage for high-cost medications.

Type 2 Diabetes Coverage: A Different Story

While Medicaid coverage for Zepbound (the obesity indication) remains limited, coverage for Mounjaro (tirzepatide for type 2 diabetes) is near-universal. The distinction matters because the active ingredient is identical. Only the brand name, NDC codes, and approved indication differ.

If a Medicaid patient has both obesity and type 2 diabetes, the prescriber may be able to prescribe tirzepatide under the Mounjaro brand for glycemic control. The patient receives the same molecule at the same doses, and weight loss occurs as a concurrent benefit. This is not off-label use; Mounjaro is FDA-approved for type 2 diabetes, and weight reduction is a documented and expected pharmacological effect.

According to the American Diabetes Association's Standards of Care (2025), tirzepatide is listed as a preferred second-line agent after metformin for patients with type 2 diabetes who have overweight or obesity, particularly when weight management is a treatment goal. The ADA specifically recommends "prioritizing agents with proven weight-loss efficacy, including tirzepatide and semaglutide, in patients with T2D and BMI ≥27."

Prescribers should document the type 2 diabetes indication clearly in the PA request. Submitting a Mounjaro PA for a patient with both conditions, using the diabetes diagnosis code (E11.x) rather than the obesity code (E66.x), is a legitimate clinical strategy that aligns prescribing with the patient's comorbid diagnoses.

What the SURMOUNT Trials Tell Medicaid Decision-Makers

The clinical data supporting tirzepatide for weight management is among the strongest for any AOM ever studied. Medicaid pharmacy and therapeutics committees reviewing Zepbound evaluate this evidence when making formulary decisions.

In SURMOUNT-1, tirzepatide at all three doses (5 mg, 10 mg, 15 mg) produced statistically significant weight loss versus placebo at 72 weeks. The 15 mg dose yielded 22.5% mean body weight reduction. More than one-third of participants on the 15 mg dose lost 25% or more of their body weight. For comparison, bariatric surgery (sleeve gastrectomy) produces mean excess weight loss of approximately 25% to 30% at 1 year.

SURMOUNT-2 studied tirzepatide in adults with type 2 diabetes and obesity. Mean weight loss at 72 weeks was 14.7% with the 15 mg dose, confirming efficacy even in a population that historically responds less robustly to AOMs due to insulin resistance.

The SURMOUNT-MMO cardiovascular outcomes trial, reported in 2024, demonstrated that tirzepatide reduced the risk of major adverse cardiovascular events (MACE) by 10% in adults with obesity and established cardiovascular disease. This cardiovascular benefit is a data point that may shift Medicaid cost-effectiveness analyses, as each prevented MACE event avoids $50,000 to $200 to 000 in acute care costs.

Tracking Formulary Changes and Staying Informed

Medicaid formularies update quarterly. A state that does not cover Zepbound today may add it within months, particularly as supplemental rebate negotiations progress and as CMS continues signaling support for AOM coverage. Patients and prescribers should monitor their state's PDL updates, which are typically posted on the state Medicaid agency's website or the contracted pharmacy benefit manager's portal.

Advocacy organizations including the Obesity Action Coalition (OAC) maintain state-by-state trackers of Medicaid AOM coverage and provide template appeal letters. The OAC's coverage map is updated quarterly and is one of the most reliable public resources for current coverage status.

For patients currently without Medicaid coverage for Zepbound, the most immediately actionable step is to ask the prescribing physician to submit a PA request anyway. A denied PA creates a documented record that enables the appeal process and, if the state later adds coverage, provides evidence of medical necessity that can accelerate retroactive authorization.